Navigation Links
HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
Date:4/16/2012

CHARLOTTESVILLE, Va., April 16, 2012 /PRNewswire/ -- HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, has been invited to present at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) conference.  The conference will be held April 18-20, 2012 at the Hilton Chicago, 720 South Michigan Avenue in Chicago, Illinois.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

The company will occupy booth No. six for recruiting purposes and present two scientific abstracts:

Atheroprone Hemodynamics and Oxidized Phospholipids Enhance Endothelial and Smooth Muscle Inflammatory Signaling

  • Presentation Date and Time: April 18th from 5:30pm to 7:30pm
  • Abstract ID Number: 580
  • Poster Presentation Number: 179
  • Presenter:  Ryan Feaver, Ph.D., HemoShear, Scientific Director

The Thrombotic Potential of the Endothelium Is Regulated by Hemodynamic Flow

  • Presentation Date and Time: April 20th from 8:00am to 10:00am
  • Abstract ID Number: 588
  • Poster Presentation Number: 521
  • Presenter:  Michael Simmers, Ph.D., HemoShear, Scientific Director

HemoShear team members attending the conference include Brett Blackman, Ph. D., co-founder, Chief Scientific Officer; Brian Wamhoff, Ph.D., co-founder, Vice President of Research and Development; Nicole Hastings, Ph.D., Vice President of Operations; Ryan Feaver, Ph.D., Scientific Director; Michael Simmers, Ph.D., Scientific Director.

About HemoShear, LLC

HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development.  Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies.  HemoShear's science leads to new medicines and improves human health.  


'/>"/>
SOURCE HemoShear, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... ComplianceOnline, the leading ... has announced its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The ... House Hotel, in Boston, MA. , The Omni Parker House Hotel, which is located ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... is exhibiting in booth 513 at the Association of Community Cancer Centers (ACCC) ... March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations to ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or ... a new risk stratification test for breast cancer, via its ... Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with a ... for developing breast cancer.   ... BreastSentry measures the fasting plasma levels ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Mass spectrometry is ... utilization of this technology is driven by its potential to perform challenging analyses in ... also some challenges that must be addressed for it to be routinely used for ...
Breaking Biology Technology:
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):